Orchard Therapeutics, a biotech business based in the US and UK, has made two key senior appointments with Robin Kenselaar joining as Senior Vice President and General Manager, EMEA commercial operations, and Brad Mathis as Vice President of US commercial operations.
Mr Kenselaar joins after almost 15 years at Sanofi Genzyme, where he built and led commercial operations throughout Europe for therapies addressing unmet needs such as rare genetic diseases, oncology and immunology.
Mr Mathis, meanwhile, was most recently Vice President, Head of US commercial operations at Sucampo Pharmaceuticals, where he helped to prepare for the launch of a therapeutic for Niemann-Pick Type C disease.
Orchard said the appointments help to build its initial commercial infrastructure across North America and EMEA prior to the Company’s first three potential product launches.
Chief Commercial Officer Jason Meyenburg said: “With three submissions for product approvals anticipated over the next three years and several additional therapies in development, the recent expansion of our commercial leadership team marks an important milestone as we prepare for the potential launches of these late-stage gene therapies, focusing especially on market access preparations and further development of patient diagnosis pathways.”